Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.21037/tcr-22-39

Scopus

PubMed

Authorship：Lead author   Language：English  

DOI： doi:10.3389/fphys.2022.990801

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/joa.13870

Scopus

PubMed

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.21873/anticanres.16471

Scopus

PubMed

Language：English   Publisher：The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery  

<p><b>Purpose:</b> Tegafur–uracil (UFT) is the standard postoperative adjuvant therapy for stage IB lung adenocarcinoma (LUAD) in Japan. This study aimed to determine whether UFT is effective in stage IB LUAD with and without <i>epidermal growth factor receptor</i> (<i>EGFR</i>) mutations.</p><p><b>Methods:</b> This retrospective study included 169 patients with stage IB LUAD who underwent complete resection at our department between 2010 and 2021. We investigated the clinicopathological and prognostic impact of <i>EGFR</i> mutations as well as the postoperative use of UFT.</p><p><b>Results:</b> <i>EGFR</i> mutation-positive cases tended to show a higher cumulative recurrence rate than <i>EGFR</i> mutation-negative cases (p = 0.081), while overall survival was comparable between the groups (p = 0.238). In the entire cohort, UFT administration was not an independent prognostic factor in the multivariate regression analysis (p = 0.112). According to a stratification analysis, UFT administration was independently associated with favorable overall survival (p = 0.031) in <i>EGFR</i> mutation-negative cases, while it was not associated with recurrence-free survival (p = 0.991) or overall survival (p = 0.398) in <i>EGFR</i> mutation-positive cases.</p><p><b>Conclusion:</b> UFT administration can improve the prognosis of <i>EGFR</i> mutation-negative LUAD but not <i>EGFR</i> mutation-positive LUAD. Thus, clinical trials of adjuvant-targeted therapy for <i>EGFR</i> mutation-positive stage IB LUAD should also be conducted in Japan.</p>

DOI： 10.5761/atcs.oa.23-00134

Scopus

PubMed

Language：Japanese   Publisher：In Vivo  

Background/Aim: The prognostic impact of adjuvant cytotoxic chemotherapy for patients with resectable locally advanced non-small cell lung cancer (NSCLC) who underwent surgery after neoadjuvant chemotherapy remains unclear. Patients and Methods: A retrospective chart review was performed to identify patients who underwent surgery following neoadjuvant therapy for clinical T3N0 or N1-N2 resectable NSCLC between 2011 and 2016 at our hospital. Survival outcomes were analyzed with the Kaplan–Meier method and a Cox proportional hazard model. Results: Thirty-eight patients were identified. The median recurrence-free survival (RFS) was 50.6 months and overall survival (OS) was 75.2 months. Patients who had undergone adjuvant chemotherapy were not associated with a favorable RFS (hazard ratio=1.01, p=0.98) or OS (hazard ratio=0.72, p=0.55), as compared with those who had not. However, subgroup analysis revealed that hazard ratio based on RFS and OS varied greatly between subgroups, suggesting that selected patients might benefit from adjuvant therapy, while others might be harmed by it. For example, in surgical-pathological stage III disease, adjuvant therapy showed a favorable RFS (HR=0.22, 95%CI=0.02-2.57, p=0.23) and OS (HR=0.36, 95%CI=0.03-4.01, p=0.40). Conversely, in surgical-pathological stage 0-II disease, adjuvant therapy showed an unfavorable RFS (HR=1.40, 95%CI=0.49-3.96, p=0.53) and OS (HR=0.95, 95%CI=0.29-3.12, p=0.93). Conclusion: Regardless of the negative findings in our overall patient cohort, our results may be beneficial in identifying patients who may likely benefit from adjuvant therapy. This contribution could assist the planning of large-scale prospective studies.

DOI： 10.21873/invivo.13723

Scopus

PubMed

Language：Japanese   Publisher：General Thoracic and Cardiovascular Surgery  

Introduction: Lung adenocarcinoma with a preoperatively elevated serum carcinoembryonic antigen (CEA) value has a relatively poor postoperative prognosis. Although surgical resection generally results in a reduction in the CEA value, the significance of the change in the CEA value on the prognostic outcome remains unclear. Methods: Our study included 133 patients who underwent lobectomy with curative intent for lung adenocarcinoma representing a preoperative CEA value > 5.0. Statistical analysis was performed using a receiver operating characteristic analysis and a stepwise Cox proportional hazards analysis. Results: Both the postoperative CEA value and postoperative-to-preoperative CEA ratio (CEA ratio) significantly affected the survival. Although the CEA ratio was not predictive of the survival in patients with postoperative CEA ≤ 6.2 ng/ml (n = 105), it was predictive in the remaining patients with postoperative CEA > 6.2 ng/ml (n = 28). Patients with postoperative CEA > 6.2 ng/ml and a CEA ratio ≥ 0.39 (n = 7) showed the worst survival outcome. According to the multivariate analysis, the CEA ratio and postoperative nodal status were significant predictors of the survival in overall patients. Conclusion: The CEA ratio may be a useful prognostic marker in patients who undergo lobectomy for lung adenocarcinoma and show postoperative CEA > 6.2 ng/ml. A high CEA ratio may indicate the presence of a subclinical residual tumor, which may lead to the development of subsequent recurrence.

DOI： 10.1007/s11748-024-02042-w

Scopus

PubMed

Language：English   Publisher：The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery  

<p><b>Purpose:</b> Regardless of the devastating outcomes of pulmonary resection for metastases from gastric cancer, a handful of patients survive long after pulmonary metastasectomy. This study aimed to identify a good candidate for pulmonary resection for metastases from gastric cancer.</p><p><b>Methods:</b> Between 2005 and 2023, 564 patients underwent pulmonary metastasectomy in our department, of which 12 patients underwent pulmonary resection for metastases from gastric cancer. Variables evaluated were the number and size of metastatic lesions, surgical procedure, disease-free interval (DFI), and the serum carcinoembryonic antigen at pulmonary metastasectomy.</p><p><b>Results:</b> The DFI following gastrectomy ≤12.5 months group had a significantly worse overall survival (OS) than the other group (p = 0.005). A comparison between DFI following gastrectomy ≤12.5 months group and DFI following gastrectomy >12.5 months group showed a significant difference in serum carcinoembryonic antigen (CEA) value at pulmonary metastasectomy (p = 0.048). The serum CEA value at pulmonary metastasectomy >5.8 ng/ml group had a significantly worse OS than the other group (p = 0.001).</p><p><b>Conclusion:</b> Pulmonary metastasectomy can be indicated in some patients with metastasis from gastric cancer who have longer DFI from gastrectomy and lower serum CEA at pulmonary metastasectomy.</p>

DOI： 10.5761/atcs.oa.24-00044

Scopus

PubMed

Authorship：Corresponding author   Language：Japanese  

DOI： 10.1159/000531840

Scopus

PubMed

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s40792-019-0731-5

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.athoracsur.2019.09.091

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/S40792-019-0652-3

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publisher：Journal of Medical Case Reports  

Background: Postoperative adjuvant systemic therapy with atezolizumab for lung cancer has been reported to be effective. Although myocarditis is a rare immune adverse event associated with atezolizumab, it can have a serious course and should be treated with caution. We herein report a case of fulminant myocarditis during adjuvant systemic therapy with atezolizumab. Case presentation: The patient was a 49-year-old Asian woman. She was diagnosed with pT2aN1M0 stage IIB (Programmed Death Ligand 1(PD-L1), 50%) after surgery for right upper lobe lung adenocarcinoma. Atezolizumab was administered following platinum-based adjuvant chemotherapy. On day 14, the patient was hospitalized because of deterioration in her general condition caused by fever. On day 16, she developed dyspnea, which worsened, and on day 17, she experienced shock. Blood tests, echocardiography, and cardiac catheterization were performed, and the patient was diagnosed with cardiogenic shock due to myocarditis. Initial measures did not improve the patient’s shock state. The patient was transferred to hospital for the use of an assistive circulatory system. Pulse steroid therapy was administered, and myocarditis showed a tendency toward improvement. A retrospective review of the patient’s history revealed a decreased lymphocyte count and an increase in the neutrophil/lymphocyte ratio, which may be useful for detecting severe immune-related adverse events. The troponin levels were elevated, but creatine phosphokinase level remained within the normal range. Conclusion: Myocarditis can be fatal due to the rapid progression of symptoms. Close follow-up, a prompt diagnosis, and therapeutic intervention are important. Decreased lymphocyte counts, increased neutrophil/lymphocyte ratios, and the measurement of multiple myocardial biomarkers are considered useful for the early diagnosis of myocarditis.

DOI： 10.1186/s13256-024-04447-w

Scopus

PubMed

Language：Japanese   Publisher：Scientific Reports  

This single-arm multi-institutional prospective study aimed to evaluate the 10-year outcomes of sublobar resection for small-sized ground-glass opacity-dominant lung cancer. Among 73 patients prospectively enrolled from 13 institutions between November 2006 and April 2012, 53 ground-glass opacity-dominant lung cancer patients underwent sublobar resection with wedge resection as the first choice. The inclusion criteria were maximum tumor size of 8–20 mm; ≥ 80% ground-glass opacity ratio on high-resolution computed tomography; lower 18F-fluorodeoxyglucose accumulation than the mediastinum; intraoperative pathological diagnosis of adenocarcinoma in situ; and no cancer cells on intraoperative cut margins. The primary endpoint was a 10-year disease-specific survival. The 53 eligible patients had a mean tumor size of 14 ± 3.4 mm and a mean ground-glass opacity ratio of 95.9 ± 7.2%. Wedge resection and segmentectomy were performed in 39 and 14 patients, respectively. The final pathological diagnoses were adenocarcinoma in situ in 47 patients (88.7%) and adenocarcinoma with mixed subtype in 6 patients (11.3%). The 10-year disease-specific survival and overall survival were 100% and 96.2%, respectively, during a median follow-up period of 120 months (range, 37–162 months). Ground-glass opacity-dominant small lung cancer is cured by sublobar resection when patients are strictly selected by the inclusion criteria of this study.

DOI： 10.1038/s41598-024-72248-8

Scopus

PubMed

Language：English  

DOI： 10.1186/s40792-024-01972-0

PubMed

Language：Japanese   Publisher：Respirology Case Reports  

Pleurectomy/decortication for malignant pleural mesothelioma is a relatively recent surgical approach for which there is a dearth of information on complications, especially in the late postoperative period. A 70-year-old man was diagnosed with right epithelioid malignant pleural mesothelioma and underwent pleurectomy/decortication. Computed tomography at 6 months after surgery revealed nodules on the surface of the right lung. These nodules gradually increased in size and were diagnosed as recurrent disease. Immunotherapy was started, but treatment was discontinued a few days after the first course due to pneumonitis. Subsequent oral prednisolone therapy for about 2 months ameliorated pneumonitis, but fistulous pyothorax developed. During attempted transbronchial occlusion of the responsible bronchus, some spigots penetrated the empyema cavity. Open window thoracotomy was performed on the following day. This case suggests that if there is no change in diameter between the proximal and distal parts of the responsible bronchus, transbronchial occlusion should not be chosen.

DOI： 10.1002/rcr2.1286

Scopus

PubMed

Language：English   Publisher：The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery  

<p>Purpose: We established a novel surgical procedure for resectable non-small-cell lung cancer (NSCLC), which involves resection of the affected lobe and regional lymph nodes without separation, namely en bloc surgery. We introduced the technical details and early and late outcomes by comparing them with those of conventional surgery.</p><p>Methods: We retrospectively analyzed patients who underwent lobectomy with hilar and mediastinal lymph node dissection for stages I–III NSCLC. A propensity score-matched analysis was performed based on demographic variables.</p><p>Results: Propensity score-matching yielded 317 pairs. En bloc surgery was not associated with a longer operation time, a higher amount of intraoperative bleeding, or a higher frequency of postoperative complications. The number of resected lymph nodes (P = 0.277) and frequency of N upstaging (P = 0.587) did not differ between the groups. However, en bloc surgery was associated with higher overall survival in comparison to conventional surgery (P = 0.012). According to a stratification analysis, the survival advantage of en bloc surgery over conventional surgery was remarkable in pathological N-positive disease (P = 0.005), whereas it disappeared in pathological N-negative disease (P = 0.147).</p><p>Conclusion: En bloc surgery is feasible and can be performed in patients with possible N-positive NSCLC.</p>

DOI： 10.5761/atcs.oa.24-00108

Scopus

PubMed

Language：Japanese   Publisher：Journal of Anatomy  

The sentinel lymph node (SN) concept has a significant impact on cancer surgery. We aimed to examine which morphology of dendritic cells (DCs) and macrophages corresponds to “preconditioning” of the SN against cancer. Although macrophages are generally able to tolerate cancer metastasis, the CD169-positive subtype is believed to be a limited exception. Immunohistochemical and morphometric analyses were performed to examine DC-SIGN-, CD68-, and CD169-positive cells in SNs and non-SNs of 23 patients with gastric cancer with or without nodal metastasis. All patients survived for >5 years without recurrence. DCs were present in the subcapsular, paracortical, and medullary sinuses, the endothelia of which expressed DC-SIGN and smooth muscle actin (SMA). In the non-SNs of patients without metastasis, subcapsular DCs occupied a larger area than SNs, and this difference was statistically significant. Conversely, subcapsular DCs were likely to have migrated to the paracortical area of the SNs. DC clusters often overlapped with macrophage clusters; however, histiocytosis-like clusters of CD169-negative macrophages showed a smaller overlap. We found a significantly larger overlap between DC-SIGN and CD169-positive clusters in SNs than in non-SNs; the larger overlap seemed to correspond to a higher cross-presentation of cancer antigens between these cell populations. DC-SIGN–CD169-double positive cells might exist within this overlap. SNs in gastric cancers are usually preconditioned as a frontier of cancer immunity, but they may sometimes be suppressed earlier than non-SNs. DC-SIGN- and CD169-positive cells appeared to decrease owing to a long lag time from the primary lesion occurrence and a short distance from the metastasis.

DOI： 10.1111/joa.14147

Scopus

PubMed

Language：Japanese  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s44215-023-00044-3

PubMed

Language：English   Publisher：BioMed Central  

症例は32歳女性。労作時呼吸困難を主訴とした。特記すべき既往はなく、喫煙歴もなかった。胸部X線検査で異常陰影を認めた。造影CTで縦隔から左胸腔内に連続する径20cm大の巨大な嚢胞性病変を認めた。MRIで多房性の嚢胞性病変を認めた。周辺臓器への浸潤を示唆する所見はなく、PET/CTで腫瘤にFDGの異常集積はみられなかった。胸膜嚢胞、心膜嚢胞、気管支原性嚢胞、または奇形性嚢胞を疑った。画像検査で病変は増大傾向を示したため、診断と治療を目的に胸腔鏡下切除術を施行した。胸腔内を占有している巨大嚢胞を穿刺吸引した。嚢胞内容液は白色の漿液で、吸引量は1850mLであった。嚢胞壁内に圧迫された横隔膜神経を認め、慎重に切離した。嚢胞の癒着はなく、嚢胞壁は容易に剥離できた。縦隔への浸潤はみられなかった。切除標本の病理組織学的検査で嚢胞壁は結合織および平滑筋を含む線維組織から構成されていた。免疫組織化学染色でリンパ管内皮のマーカーであるD2-40に陽性を呈したことからリンパ管腫と診断した。術後3日および17日にデジタルX線動画撮影を行い、横隔膜の上下運動を評価した。呼吸機能は徐々に改善した。

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.21037/qims-22-1149

DOI： doi:10.1002/rcr2.1052

Other Link： https://doi.org/10.1002/rcr2.1052

Language：Japanese   Publisher：鹿児島県臨床外科学会  

19歳女性。大学入学時の検診にて胸部異常陰影を指摘され、前医の精査で胸腺腫の疑いで当科へ紹介となった。術前CTでは大動脈弓左側から左肺動脈に32×17×37mmの一部造影効果を認める多房性の嚢胞性腫瘤が認められ、MRIではT1で腫瘤は内部低信号、T2では内部高信号を呈した。以上、これらの所見を踏まえて、本症例は左縦隔腫瘍と診断のもと、当科オリジナルの3ポートアプローチ(3アーム+1アシスト)でロボット支援下手術が施行された。その結果、経過良好にて患者は術後5日で自宅退院となった。

DOI： doi:10.1002/rcr2.1023

Other Link： https://doi.org/10.1002/rcr2.1023

Language：English   Publisher：European Journal of Cardio-thoracic Surgery  

OBJECTIVES: The present study investigated whether or not pleural anthracosis is associated with changes in the pleural lymphatic structures or function, which would interfere with nodal skip metastasis. METHODS: This study comprised 2 different case series. In the first series, we observed pleural lymphatic drainage using near-infrared fluorescent endoscopy by the subpleural injection of indocyanine green immediately after thoracotomy for lung cancer. We also performed a histological assessment of the pleura. In the second series, we reviewed the nodal metastatic pattern (skip or non-skip metastasis) in pathological N2 lung cancer involving the pleura. These findings were compared with the severity of pleural anthracosis, which was quantified by thoracoscopic vision and a software-based imaging analysis. RESULTS: In the first series (n = 42), pleural lymphatic drainage was not visualized in 19 (45%) patients who had relatively severe anthracosis, while it was visualized in the remaining 23 (55%) patients who had relatively minimal anthracosis. Histologically, severe anthracosis was associated with pleural thickening accompanied by a decreased incidence of straight-running lymphatic vessels and, in turn, an increased incidence of short lymphatic vessels, which was suggested to be the result of pleural remodelling. In the second series (n = 53), a skip metastatic pattern was found in 24 (45%) patients who predominantly had less-severe anthracosis, while a non-skip metastatic pattern was found in 29 (55%) patients who predominantly had severe anthracosis. CONCLUSIONS: Pleural anthracosis was associated with pathological changes in the pleural lymphatics and decreased pleural lymphatic drainage, thereby interfering with nodal skip metastasis.

DOI： 10.1093/ejcts/ezac123

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

DOI： doi:10.1016/j.xjtc

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respirology Case Reports  

Bronchogenic cysts that occur within the diaphragm are rare and difficult to diagnose preoperatively. We experienced the case of a patient with an abnormally high serum carbohydrate antigen 19-9 (CA19-9) level before surgery. The diagnosis of intradiaphragmatic bronchogenic cyst was made at the time of surgery. The patient was a 50-year-old woman with upper abdominal pain with an incidentally elevated serum CA19-9. Although the tumour location could not be established on images, a tumour within the diaphragm was confirmed during the operation. The diaphragm was incised and the tumour was removed together with the capsule. Bronchial cysts were diagnosed histopathologically, and immunohistochemical examination revealed that the bronchial epithelial cells were positive for CA19-9. When managing patients with bronchogenic cysts in the diaphragm, it is difficult to make a preoperative diagnosis or determine the location of the tumour; thus, careful planning is required before surgery.

DOI： 10.1002/rcr2.838

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Pharmaceutical and Biomedical Analysis  

There are more than 150 types of naturally occurring modified nucleosides, which are believed to be involved in various biological processes. Recently, an ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UHPLC-ESI-MS/MS) technique has been developed to measure low levels of modified nucleosides. A comprehensive analysis of modified nucleosides will lead to a better understanding of intracellular ribonucleic acid modification, but this analysis requires high-sensitivity measurements. In this perspective, we established a highly sensitive and quantitative method using the newly developed ion source, UniSpray. A mass spectrometer was used with a UniSpray source in positive ion mode. Our UHPLC-UniSpray-MS/MS methodology separated and detected the four major nucleosides, 42 modified nucleosides, and dG15N5 (internal standard) in 15 min. The UniSpray method provided good correlation coefficients (>0.99) for all analyzed nucleosides, and a wide range of linearity for 35 of the 46 nucleosides. Additionally, the accuracy and precision values satisfied the criteria of <15% for higher concentrations and <20% for the lowest concentrations of all nucleosides. We also investigated whether this method could measure nucleosides in biological samples using mouse tissues and non-small cell lung cancer clinical specimens. We were able to detect 43 and 31 different modified nucleosides from mouse and clinical tissues, respectively. We also found significant differences in the levels of N6-methyl-N6-threonylcarbamoyladenosine (m6t6A), 1-methylinosine (m1I), 2′-O-methylcytidine (Cm), 5-carbamoylmethyluridine (ncm5U), 5-methoxycarbonylmethyl-2-thiouridine (mcm5S2U), and 5-methoxycarbonylmethyl-2′-O-methyluridine (mcm5Um) between cancerous and noncancerous tissues. In conclusion, we developed a highly sensitive methodology using UHPLC-UniSpray-MS/MS to simultaneously detect and quantify modified nucleosides, which can be used for analysis of biological samples.

DOI： 10.1016/j.jpba.2021.113943

Scopus

PubMed

Language：Japanese  

DOI： 10.3892/or.2020.7839

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s40792-020-00860-7

Language：Japanese   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s00330-019-06463-7

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.jtocrr.2020.100019

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1510/mmcts.2019.030

Language：Japanese   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s11307-018-1290-z.

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.15761/IMM.1000347

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.31487/j.SCR.2018.03.027

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.5761/atcs.cr.16-00250

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1177/0218492316660452

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Event date： 2024.3

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：宮崎  

Event date： 2024.3

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：宮崎  

Event date： 2023.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2023.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：千葉  

Event date： 2023.10

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：仙台  

Event date： 2023.7

Venue：大分  

Event date： 2023.7

Venue：大分  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.7

Venue：新潟  

Event date： 2023.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：横浜  

Event date： 2023.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2023.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2023.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2023.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：長崎  

Event date： 2023.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：長崎  

Event date： 2022.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2022.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2022.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2022.10

Presentation type：Oral presentation (general)  

Venue：横浜  

Event date： 2022.10

Presentation type：Oral presentation (general)  

Venue：横浜  

Event date： 2022.7

Presentation type：Oral presentation (general)  

Venue：長崎  

Event date： 2022.7

Presentation type：Oral presentation (general)  

Venue：長崎  

Event date： 2022.6

Presentation type：Oral presentation (general)  

Venue：沖縄  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：岐阜  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：岐阜  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：web  

Event date： 2022.5

Presentation type：Oral presentation (general)  

Venue：web  

Event date： 2022.4

Language：English  

Venue：Web開催  

Event date： 2022.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：web  

Event date： 2022.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2022.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2022.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2022.2

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：Web開催  

Event date： 2021.11

Language：Japanese  

Venue：横浜  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2021.11

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：Web開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：横浜  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.10

Language：English  

Venue：Web開催  

Event date： 2021.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：Web開催  

Event date： 2021.2

Venue：Web開催  

Event date： 2021.2

Venue：Web開催  

Event date： 2021.2

Venue：Web開催  

Event date： 2021.2

Venue：Web開催  

Event date： 2020.10

Venue：Web開催  

Event date： 2020.10

Venue：Web開催  

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2019.9

Language：English   Presentation type：Poster presentation  

Venue：千葉  

Event date： 2019.8

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：宮崎  

Event date： 2019.8

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：宮崎  

Event date： 2019.8

Language：English   Presentation type：Oral presentation (general)  

Venue：宮崎  

Event date： 2019.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2019.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2019.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2019.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.5

Language：English   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2019.3

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：沖縄  

Event date： 2019.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：佐賀  

Event date： 2019.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：佐賀  

Event date： 2018.8

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2018.8

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2018.8

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2018.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2018.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京  

Event date： 2018.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：熊本  

Event date： 2018.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：熊本  

Event date： 2017.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡市  

Event date： 2017.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡市  

Event date： 2017.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡市  

Event date： 2017.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京都  

Event date： 2016.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2016.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2016.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2016.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡  

Event date： 2016.10

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：岡山  

Event date： 2016.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2016.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2016.7

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：鹿児島  

Event date： 2016.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：名古屋  

Event date： 2016.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：名古屋  

Event date： 2016.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：名古屋  

Event date： 2016.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.5

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都  

Event date： 2016.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2016.4

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪  

Event date： 2016.2

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：北九州  

Event date： 2015.6

Language：Japanese  

Venue：東京  

国内学会

Event date： 2014.11

Language：Japanese  

Venue：京都  

国内学会

Event date： 2014.5

Language：Japanese  

Venue：福岡  

国内学会

Event date： 2014.4

Language：English  

Venue：京都  

国際学会

Event date： 2014.4

Language：Japanese  

Venue：京都  

国内学会

Event date： 2013.12

Language：Japanese  

Venue：鹿児島  

研究会

Event date： 2013.10

Language：English  

Venue：オーストラリア / シドニー  

国際学会

Event date： 2013.7

Language：Japanese  

Venue：福岡  

研究会

Event date： 2013.5

Language：Japanese  

Venue：愛知  

国内学会

Event date： 2013.4

Language：Japanese  

Venue：福岡  

国内学会

Event date： 2012.11

Language：Japanese  

Venue：岡山  

国内学会

Event date： 2012.10

Language：Japanese  

Venue：福岡  

国内学会

Event date： 2012.7

Language：Japanese  

Venue：長崎  

国内学会

Event date： 2012.5

Language：Japanese  

Venue：秋田  

国内学会

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese